undamentalytics Newsletter
Sign in

Rhythm Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Rhythm Pharmaceuticals, Inc.'s operations generated −$116m of cash; it spent $953,000 on capital projects, leaving free cash flow of −$117m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−23−29−62−123−122−146−173−136−114−116−105
Depreciation and amortisation0001111111—
Stock-based pay1261217212033406787
Capital spending10130000010
Free cash flow−24−30−63−126−122−146−174−136−114−117−105
Free cash flow after stock pay−25−32−69−138−140−167−194−169−154−183−193
Shares issued—126163161—162131493934—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ANAB vs RYTMIDYA vs RYTMPBYI vs RYTMLGND vs RYTM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rhythm Pharmaceuticals, Inc.